GlassScriptPhysician profile
Nicholas J Trudo
NPI 1467938290
$6,750.49
in general payments reported to CMS, 2019-2025
38 companies · $3,563 in 2025
The $3,563 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $3,065 · 2025: $3,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,750.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $613.82 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $565.53 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $550.45 | 2024-2025 | Tepezza, Evenity, Prolia |
| Novo Nordisk INC | $529.81 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $520.71 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $466.14 | 2024-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Corcept Therapeutics | $377.15 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $309.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $304.27 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Cequr Corporation | $245.95 | 2024-2025 | Cequr Simplicity |
| Astellas Pharma US INC | $203.35 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $163.40 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $159.92 | 2024-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $158.92 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $154.87 | 2024-2025 | Freestyle Libre 3 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rgh Enterprises LLC | $142.43 | 2025 | |
| Radius Health, INC. | $120.41 | 2024-2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $103.16 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $102.88 | 2023-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.22 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Madrigal Pharmaceuticals | $94.52 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $85.26 | 2024 | Tirosint, Licart, Flector |
| Astrazeneca Pharmaceuticals LP | $79.76 | 2024-2025 | Farxiga |
| Ascensia Diabetes Care US INC. | $74.30 | 2024-2025 | |
| Antares Pharma, INC. | $67.05 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $64.64 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $54.44 | 2025 | |
| Chiesi USA, INC. | $53.71 | 2025 | Mycapssa |
| Abbvie INC. | $47.59 | 2025 | |
| Tolmar, INC. | $43.55 | 2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $42.18 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Esteve Pharmaceuticals LLC | $34.94 | 2025 | Metopirone |
| Acella Pharmaceuticals, LLC | $28.79 | 2024 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $22.89 | 2024 | Crysvita |
| Sequel Med Tech, LLC | $20.87 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $16.57 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $16.10 | 2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $14.56 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Trudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.